These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25588379)

  • 21. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
    Ng CM; Patnaik A; Beeram M; Lin CC; Takimoto CH
    Cancer Chemother Pharmacol; 2011 May; 67(5):985-94. PubMed ID: 20614121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigm.
    Ananthakrishnan R; Menon S
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):153-69. PubMed ID: 22118941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
    Workman P; Aboagye EO; Chung YL; Griffiths JR; Hart R; Leach MO; Maxwell RJ; McSheehy PM; Price PM; Zweit J;
    J Natl Cancer Inst; 2006 May; 98(9):580-98. PubMed ID: 16670384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly.
    Tranchand B; Laporte S; Glehen O; Freyer G
    Crit Rev Oncol Hematol; 2003 Nov; 48(2):199-214. PubMed ID: 14607383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translation of central nervous system occupancy from animal models: application of pharmacokinetic/pharmacodynamic modeling.
    Melhem M
    J Pharmacol Exp Ther; 2013 Oct; 347(1):2-6. PubMed ID: 23857976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microdialysis: a technique for pharmacokinetic-pharmacodynamic studies of oncological drugs.
    Wei YH; Xu LZ; Shen Q; Li FZ
    Curr Pharm Biotechnol; 2009 Sep; 10(6):631-40. PubMed ID: 19619119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy may be delivered based on an integrated view of tumour dynamics.
    Ribba B; You B; Tod M; Girard P; Tranchand B; Trillet-Lenoir V; Freyer G
    IET Syst Biol; 2009 May; 3(3):180-90. PubMed ID: 19449978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
    Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
    AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microdialysis for pharmacokinetic-pharmacodynamic studies.
    Yu W; Cheng Q; Feng J; Li F
    Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
    Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacodynamic and pharmacokinetic modeling via mixed effects.
    Piotrovsky VK
    Curr Opin Drug Discov Devel; 2000 May; 3(3):314-30. PubMed ID: 19649865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    Xenobiotica; 2015 Jan; 45(1):19-28. PubMed ID: 25050790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development.
    Bernard A; Kimko H; Mital D; Poggesi I
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1057-69. PubMed ID: 22632710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current problems in surgical oncology: 1. Theoretical models in oncology and their implications in surgical therapy].
    Vasilescu C
    Chirurgia (Bucur); 2011; 106(1):17-22. PubMed ID: 21523955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated network-based mechanistic model for tumor growth dynamics under drug administration.
    Ribeiro D; Pinto JM
    Comput Biol Med; 2009 Apr; 39(4):368-84. PubMed ID: 19285661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.